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Abstract
Objective: Cannabinoid receptors and their ligands have been implicated in the regulation of various physiological processes but their role in osteoarthritis has not been investigated. The aim of this study was to evaluate the role of the type 2 cannabinoid receptor (Cnr2) in regulating susceptibility to osteoarthritis in mice. 
Methods: We analysed the severity of knee osteoarthritis as assessed by the OARSI scoring system in mice with targeted deletion of Cnr2 (Cnr2-/-) and wild type (WT) littermates. Studies were conducted in mice subjected to surgical destabilisation of the medial meniscus (DMM) and in those with spontaneous age-related OA.
Results: Osteoarthritis was more severe following DMM in the medial compartment of the knee in Cnr2-/- compared with WT mice (mean ± sem score = 4.9±0.5 vs. 3.6±0.3; p=0.017). Treatment of WT mice with the CB2-selective agonist HU308 following DMM reduced the severity of OA in the whole joint (HU308 = 8.4±0.2 vs. vehicle = 10.4±0.6; p=0.007). Spontaneous age related osteoarthritis was also more severe in the medial compartment of the knee in 12-month old Cnr2-/- mice compared with WT (5.6±0.5 vs. 3.5±0.3, p=0.008). Cultured articular chondrocytes from Cnr2-/- mice produced less proteoglycans in vitro than wild type chondrocytes.
Conclusion: These studies demonstrate that the Cnr2 pathway plays a role in the pathophysiology of osteoarthritis in mice and shows that pharmacological activation of CB2 has a protective effect. Further studies of the role of cannabinoid receptors in the pathogenesis of osteoarthritis in man are warranted. 

Introduction
The endocannabinoid system has been implicated in the control of a variety of physiological processes including the regulation of appetite and energy balance; the perception of pain; and regulation of the immune responses  ADDIN REFMGR.CITE 1. There are two classical cannabinoid receptors which belong to the G-protein coupled receptor superfamily and signal through the Gi/o protein. The type 1 cannabinoid receptor (CB1), was first to be identified. It is highly expressed in the nervous system and mediates the psychotropic and neurological effects of cannabinoids. The type 2 receptor (CB2) is mainly expressed in peripheral tissues and has been implicated in regulating the immunomodulatory effects of cannabinoids. 
The best characterised endogenously produced cannabinoid receptor ligands are N-arachidonoylethanolamine (anandamide) and 2-arachidonoyl glycerol (2-AG) which are small molecules produced by breakdown of membrane phospholipids. Both are agonists at the type 1 and 2 cannabinoid receptors. The Cannabis sativa plant contains a large number of cannabinoids but the best known are Δ9-tetrahydrocannabinol, which acts as an agonist at both receptors and is responsible for the psychotropic effects of cannabis, and cannabidiol, which acts as an antagonist or inverse agonist at CB1 and CB2 receptors. Many synthetic cannabinoids have been produced which act as agonists, antagonists or inverse agonists at one or both cannabinoid receptors  ADDIN REFMGR.CITE 1. Cannabinoids have been shown to interact with various other receptors including GPR55, nicotinic acetyl choline receptors, calcium channels, voltage gated potassium channels, and transient receptor potential vanilloid receptors  ADDIN REFMGR.CITE 1. 

Over recent years there has been increasing interest in the potential role of the endocannabinoid system in the pathophysiology of bone and joint disease 2. Previous studies have shown that mice with targeted inactivation of the type 1 cannabinoid receptor (Cnr1-/- mice) have increased peak bone mass due to an osteoclast defect, but develop osteoporosis with increasing age due to reduced bone formation  ADDIN REFMGR.CITE 3,4,5. Mice with targeted inactivation of the type 2 cannabinoid receptor (Cnr2-/- mice) have been reported to have normal or slightly reduced peak bone mass but also develop osteoporosis with increasing age in association with increased bone turnover  ADDIN REFMGR.CITE 6,7.
Cannabinoids and their receptors have also been implicated in the pathogenesis of arthritis. For example, cannabidiol has been shown to reduce cartilage damage in a mouse model of inflammatory arthritis  ADDIN REFMGR.CITE 8 and cannabinoid receptor agonists have been found to protect against collagen-induced arthritis  ADDIN REFMGR.CITE 9 and to inhibit IL-1 induced cartilage degradation in vitro  ADDIN REFMGR.CITE 10. Cannabinoid receptors are expressed in articular chondrocytes  ADDIN REFMGR.CITE 10 and in human synovial tissue  ADDIN REFMGR.CITE 11. Furthermore, 2-AG and anandamide have been detected in synovial fluid from humans with osteoarthritis (OA) and rheumatoid arthritis  ADDIN REFMGR.CITE 11. Given the importance of subchondral bone in the pathogenesis of osteoarthritis  ADDIN REFMGR.CITE 12,13, the regulatory role of cannabinoid receptors in bone metabolism 2 and the fact that CB2 is expressed in chondrocytes and other joint tissues  ADDIN REFMGR.CITE 11,10 the aim of the present study was to determine if the type 2 cannabinoid receptor plays a role in the pathogenesis of osteoarthritis in mice. 

Materials and Methods
Materials
All reagents were obtained from Sigma Aldrich (Dorset, UK) unless otherwise stated. The CB2-selective agonist HU308 was purchased from Tocris Biosciences (Bristol, UK). Dulbecco’s Modified Eagle’s Medium (D-MEM) was obtained from Invitrogen (Paisley, UK), foetal calf serum was obtained from Fisher Scientific (Leicestershire, UK), and l-glutamine and penicillin/streptomycin were obtained from Invitrogen (Paisley, UK). Alcian Blue 8GX and Safranin-O were purchased from TAAB Lab (Berkshire, UK), and Harris Haematoxylin from Raymond A Lamb (Eastbourne, UK). 

Animals
Mice targeted with inactivation of Cnr2, were generated as previously described 14 and were obtained from Dr. Susana Winfield at the National Institutes of Health. Extensive previous studies have been performed on this strain of mice (reviewed by Buckley 15).  They have been reported to exhibit reduced bone density and various other defects in responses to treatment with cannabinoid receptor ligands including a reduced threshold for detection of pain 15. These mice are of normal size and body weight, reproduce normally and have normal survival and locomotor activity. These mice were backcrossed with wild type C57BL/6 mice for at least 10 generations to create Cnr2-deficient mice (Cnr2-/- mice) on C57BL/6 background. The wild type (WT) and Cnr2-/- mice used in these experiments were generated by mating heterozygote breeding pairs. The mice were housed in pathogen-free rooms of a designated animal facility, at constant temperature, under a 12-hour dark-to-light cycle and with water and pelleted standard commercial diet made available ad libitum. All animal experiments were approved by the Animal Welfare and Ethical Review Body of the University of Edinburgh and were conducted in accordance with the UK Animals (Scientific Procedures) Act 1986.

Osteoarthritis induced by destabilisation of the medial meniscus
Osteoarthritis was induced in eight week old male mice by surgically induced destabilisation of the medial meniscus (DMM) essentially as described by Glasson et al. 16 under general anaesthesia with ketamine hydrochloride 76mg/kg and medetomidine hydrochloride 1mg/kg given intraperitoneally. Following section of the medial meniscotibial ligament, the joint capsule and skin were the closed and anaesthesia reversed by an intraperitoneal injection of atipamezole hydrochloride 1mg/kg. Following DMM the mice were followed up for eight weeks and killed at age 16 weeks by inhalation of carbon dioxide. The lower limbs were carefully dissected free, the skin was removed, and the limbs were fixed for 24 hours in 4% formaldehyde and then kept in ethanol (70% v/v) until further analysis. We elected not to perform sham surgery on the contralateral knee based on animal welfare grounds since previous studies had shown no difference in OA scores between sham-operated and non-operated knee joints using this model  ADDIN REFMGR.CITE 16,17 and since the primary aim of the experiment research was to evaluate the response to DMM in Cnr2-/- and wild type mice. A total of nine Cnr2-/- and nine wild type mice were studied in this experiment.

Effect of the Cnr2 agonist HU308 on DMM induced osteoarthritis
We performed an additional DMM experiment in which eight week old Cnr2-/- and wild type mice were treated with the CB2-selective agonist HU308  ADDIN REFMGR.CITE 18 or vehicle immediately after surgery. The HU308 was initially dissolved in dimethylsulfoxide (DMSO) and the DMSO/HU308 solution was dissolved in 5% (w/v) mannitol and 0.5% (w/v) gelatin in distilled water. The HU308 was administered twice a week intraperitoneally at a final dose of 1mg/kg for eight weeks. This dosage regimen was chosen since we have previously shown that it protects against ovariectomy induced bone loss in mice  ADDIN REFMGR.CITE 7. The control group of mice received vehicle alone intraperitoneally twice a week for eight weeks. Both groups of mice were then killed by inhalation of carbon dioxide at age 16 weeks and the lower limbs were isolated as described above. A total of 11 mice were treated with vehicle (five WT and six Cnr2-/- mice) and 12 mice were treated with HU308 (seven WT and five Cnr2-/- mice) in this experiment.



Spontaneous age-related osteoarthritis 
A third experiment was performed in which we compared the severity of spontaneous age-related osteoarthritis in Cnr2-/- and wild type mice. For these experiments we performed histology and MicroCT analysis of the knee joints of 12-month old female Cnr2-/- mice and compared the findings with aged and gender matched wild type littermates that had not undergone any specific experimental procedures. The mice were killed by inhalation of carbon dioxide, and the lower limbs were processed as described for the DMM experiments.  A total of five Cnr2-/- and five wild type mice were included in this experiment.

Analysis of periarticular bone by micro computed tomography 
Analysis of periarticular bone was performed by microCT using a Skyscan 1172 instrument set at 60kV and 167µA, at a resolution of 5µm. The regions of interest analysed were the subchondral trabecular bone situated within the tibial epiphysis and the subchondral bone plates of the tibial plateau (Supplementary Figure 1). The microCT analyses were performed in the coronal plane. Following acquisition, the images were reconstructed using the Skyscan NRecon programme and analysed using Skyscan CTAn software. 

Histological analysis
Histological analysis was performed on fixed whole joints that had been decalcified in 10% formic acid for 1 week. The joints were then processed and embedded in paraffin wax according to standard techniques. A Leica microtome (Solms, Germany) was used to take 7m coronal sections through the entire joint at 45m intervals, yielding 10-13 different levels. Sections were then stained with Safranin-O and Haematoxylin according to standard techniques. Histological evaluation of the severity of osteoarthritis was performed by an observer (AS) blinded to genotype and pharmacological treatment according to the Osteoarthritis Research Society International (OARSI) scoring system 19. Scores were generated from separately from the medial tibial plateau (MTP), the medial femoral condyle (MFC), the lateral tibial plateau (LTP) and lateral femoral condyle (LFC) (Supplementary Figure 1). We then added the scores from the tibial and femoral articular cartilage to give a summated score for the medial and lateral compartments (ranging from a minimum score of 0 to a maximum of 12). Finally we calculated summated scores for the entire joint in which the scores were combined from the medial and lateral compartments (ranging from a minimum score of 0 to a maximum of score of 24). 
A randomly selected sample of 26 joints were assessed by a second observer (AEB) who was also 
blinded to genotype and treatment allocation to test reproducibility of the scoring system.

Chondrocyte isolation from articular cartilage
Articular chondrocytes were isolated as previously described  ADDIN REFMGR.CITE 20. We pooled the chondrocytes from several mice aged 5-6 days old, for each experiment in order to obtain sufficient numbers of cells. 

Proteoglycan production by articular chondrocytes  
Articular chondrocytes were cultured in gelatin-coated 12 well plates at a density of 5 x 104 cells/well in standard D-MEM at 37oC. The medium 
was refreshed every 2 days for a total of 12 days when cell number was determined by Alamar Blue staining as described  ADDIN REFMGR.CITE 21.






Figure 1. Response to DMM in wild type and Cnr2-/- mice. Panel A shows OARSI scores from the femoral condyle and tibial plateau in the medial and lateral compartment of non-operated knee joints of wild type (WT) and Cnr2-/- mice. The maximum score for each compartment is 12.  Panel C shows similar data in the medial and lateral compartment of knee joints that underwent DMM. Panels B and D show representative photomicrographs from the non-operated and DMM operated joints, respectively. Areas of cartilage damage at the tibial plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns represent the mean and vertical bars the standard error of the mean from nine wild type and nine Cnr2-/- mice.  The p-value refers to the difference between Cnr2-/- and wild type mice as assessed by Student’s t-test.







Table 1. MicroCT analysis of tibial subchondral bone of wild type (WT) and Cnr2-/- mice 

	Non-operated  	DMM
	WT(n=9)	Cnr2-/-(n=9)	WT(n=9)	Cnr2-/-(n=9)
BV/TV (%)	25.09 ± 1.08	23.81 ± 1.47	25.64 ± 0.83	25.79 ± 0.94
Tb.N (1/mm)	5.47 ± 0.16	4.90 ± 0.12**	5.25 ± 0.14	5.27 ± 0.19
Tb.Th (m)	45.87 ± 1.33	48.49 ± 2.34	48.85 ± 0.96	49.14 ± 1.68
Tb.Sp (m)	163.09 ± 3.50	177.62 ± 4.85*	169.63 ± 1.82	171.40 ± 3.22
Tb.Pf (1/mm)	7.95 ± 1.32	8.76 ± 1.49	7.48 ± 1.55	3.81 ± 1.80
Medial bone plate thickness (m)	121.38 ± 10.07	142.58 ± 10.06	137.38 ± 5.50	139.03 ± 10.45
Lateral bone plate thickness (m)	86.67 ± 4.50	92.30 ± 6.17	94.12 ± 2.73	100.84 ± 4.07

BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. The values shown are mean ± sem . *p = 0.02 and **p = 0.009 Cnr2-/- vs. wild type by Student’s t-test.




The cultures were then fixed in 70% (v/v) ethanol and stained for proteoglycans using 1% Alcian Blue in 0.1M HCl. The wells were washed to remove excess dye and 0.8ml 4M guanidine HCl was added to each well to dissolve the dye. The plates were incubated overnight at room temperature and the absorbance was read at 600nm on a microplate reader using an Alcian Blue dye standard curve (concentration range 0-40nM) prepared in the same solvent 22. The absorbance was corrected for cell number and the amount of proteoglycan produced per cell was calculated in arbitary units. 

Statistical analysis and sample size
Statistical analyses were performed using IBM SPSS Statistics, version 19 (Armonk, NY). The sample size for the initial DMM experiment was chosen to provide 84% power to detect a 1.6 standard deviation difference in severity of osteoarthritis between Cnr2-/- and wild type mice. This effect size was chosen since we felt that it was a biologically important difference. The sample size for the HU308 experiment and the age-related experiment was chosen to detect a two standard deviation difference between groups. The inter-observer agreement between the OARSI scores of AS and AEB was assessed by calculating the kappa co-


efficient. For all experiments we determined if the data were normally distributed using the Shapiro-Wilk test. For data that were normally distributed, between group comparisons were performed by Student’s t-test. For data that were not normally distributed, comparisons were performed using the Mann–Whitney U test. We combined the results of the in vivo experiments by meta-analysis using Review Manager version 5.3 software (Cochrane Collaboration) 23. Unless otherwise stated the values shown are the mean and standard error of mean (sem). The significance level was set at p≤0.05 for individual experiments.

Results
Reproducibility of scoring system
Reproducibility of the OARSI scoring system used to assess severity of OA was independently assessed by two observers (AS and AEB) in 26 out of 106 samples (24.5%). This showed an inter-observer kappa co-efficient of 0.753 (p<0.001), which is considered substantial 24.

Effect of Cnr2 deficiency in DMM induced osteoarthritis 
There was no significant difference in OARSI scores for the non-operated joints between Cnr2-/- and WT mice (Figure 1A and 1B). The DMM operated joints showed a significant increase in OARSI score in the medial compartment when compared with the non-operated joints. Values in the non-operated joint in wild type mice were (mean ± sem) 1.6 ± 0.4 compared to 3.6 ± 0.3 in the DMM operated joint representing a 124% increase (p<0.001). Corresponding values in Cnr2-/- mice were 2.1 ± 0.7 in the non-operated joint versus 4.9 ± 0.5 in the DMM operated joint representing a 134% increase (p=0.002). There was no significant increase in OARSI score following DMM in the lateral compartment as compared with the non-operated knee in either genotype group.  The OARSI scores were significantly higher in the medial compartment of DMM operated Cnr2-/- mice when compared with wild type (4.9 ± 0.5 vs. 3.6 ± 0.3, p=0.017) (Figure 1C and 1D). There was no significant difference in OARSI scores between genotype groups in the lateral compartment (Figure 1C) or when the scores were combined for the whole joint (8.2 ± 0.9 vs. 6.6 ± 0.9, p=0.201). These results indicate DMM induces osteoarthritis predominantly affecting the medial joint compartment and that within this compartment Cnr2 deficiency is associated with significantly worse osteoarthritis than in wild type mice. 







Figure 2. Effect of HU308 on osteoarthritis following DMM in wild type (WT) and Cnr2-/- mice
Panel A shows OARSI scores from the femoral condyle and tibial plateau in the medial and lateral compartments of knee joints in wild type (WT) mice following DMM and treatment with vehicle or HU308. The maximum score for each compartment is 12. Panel C shows similar data from Cnr2-/- mice. Panels B and D show representative photomicrographs from the operated joints in WT and Cnr2-/- mice, respectively. Areas of cartilage damage at the tibial plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns represent the mean and vertical bars the standard error of the mean from five vehicle-treated wild type mice, seven HU308-treated wild type mice, six vehicle treated Cnr2-/- mice and five HU308 treated Cnr2-/- mice. The p-values refer to differences between the HU308 and vehicle treated mice as assessed by Mann–Whitney U test.




Table 2. MicroCT analysis of tibial subchondral bone following HU308 or vehicle treatment.

	HU308 	Vehicle
	WT(n=7)	Cnr2-/-(n=5)	WT(n=5)	Cnr2-/-(n=6)
BV/TV (%)	27.30 ± 0.98	28.19 ± 1.12	28.12 ± 1.05	29.24 ± 1.03
Tb.N (1/mm)	6.45 ± 0.24	5.92 ± 0.23	6.38 ± 0.22	6.10 ± 0.36
Tb.Th (m)	42.44 ± 1.41	47.67 ± 1.14*	44.22 ± 2.01	48.29 ± 1.86
Tb.Sp (m)	168.13 ± 6.36	174.26 ± 2.16	166.00 ± 4.41	170.70 ± 5.06
Tb.Pf (1/mm)	-7.69 ± 2.77	-2.59 ± 2.18	-6.12 ± 2.30	-5.56 ± 3.32
Medial bone plate thickness (m)	71.57 ± 4.98	76.65 ± 4.26	76.11 ± 6.25	78.79 ± 3.70
Lateral bone plate thickness (m)	56.83 ± 2.19	65.98 ± 5.14	61.22 ± 2.80	67.10 ± 4.83

BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. Data is presented as means ± sem. The number of mice in each group are indicated. * indicates p = 0.015 Cnr2-/- vs. wild type assessed by Student’s t-test.




Effects of Cnr2 deficiency on subchondral bone in DMM induced osteoarthritis
In order to determine if the predisposition to osteoarthritis following DMM was associated with abnormalities in subchondral bone we performed microCT analysis of tibial subchondral bone in WT and Cnr2-/- mice. The results are summarised in Table 1. In non-operated joints, Cnr2-/- mice had significantly lower trabecular number (Tb.N) (p=0.009), and increased trabecular separation (Tb.Sp) (p=0.02), than in WT mice but none of the other parameters differed significantly. In the joints undergoing DMM, trabecular pattern factor (Tb.Pf) was slightly lower in Cnr2-/- mice compared with WT but the difference was not significant. Analysis of the tibial subchondral bone plates showed no difference between genotypes and no significant differences between non-operated and DMM operated joints. 

Effect of the Cnr2 agonist HU308 on DMM induced osteoarthritis 
In view of the fact that Cnr2-/- mice developed substantially more severe osteoarthritis following DMM than wild type littermates, we performed a further experiment to evaluate the effect the CB2-selective agonist HU308 in the DMM model. For this experiment Cnr2-/- and wild type mice were administered HU308 or vehicle intraperitoneally at a dose of 1mg/kg twice weekly for eight weeks following DMM. Administration of HU308 to WT mice partially protected against the development of osteoarthritis in both joint compartments. For the medial compartment the mean ± sem OARSI score was 4.1 ± 0.2 in the HU308 group compared with 5.4 ± 0.6 in the vehicle group (p=0.022) and corresponding score in the lateral compartment were 4.3 ± 0.2 vs. 5.0 ± 0.0, p=0.018) (Figure 2A and 2B). When the scores were combined for both compartments, the difference between HU308 and vehicle treated mice was significant (8.4 ± 0.2 vs. 10.4 ± 0.6, p=0.007).
In contrast, administration of HU308 to Cnr2-/- mice had no significant protective effect on the severity of osteoarthritis (Figure 2C and 2D). These results support the hypothesis that Cnr2 is involved in the pathogenesis of osteoarthritis induced by DMM by showing that HU308 protects from cartilage damage in wild type mice but not in Cnr2-/- mice. 

Effect of the Cnr2 agonist HU308 on subchondral bone in DMM induced osteoarthritis
There was no significant difference in the tibial subchondral trabecular bone in mice treated with HU308 or placebo either between genotypes (Cnr2-/- vs. WT) or within genotypes (Table 2). In addition, HU308 treatment had no significant effect on subchondral bone plate thickness in either genotype group (Table 2).  



Figure 3. Age-related osteoarthritis in wild type (WT) and Cnr2-/- mice. Panel A shows OARSI score from femoral condyle and tibial plateau in the medial and lateral compartments of knee joints in 12-month old wild type (WT) and Cnr2-/- female mice. The maximum score for each compartment is 12. Panel B shows representative photomicrographs from joints of WT and Cnr2-/- mice. Areas of cartilage damage at the tibial plateau (black arrows) and femoral condyle (red arrows) are indicated. Columns represent the mean and vertical bars the standard error of the mean (sem) from five wild type and five Cnr2-/- mice. The p-value refers to the difference between Cnr2-/- and wild type assessed by Mann–Whitney U test. 
Effect of Cnr2 on spontaneous age-related osteoarthritis
A further experiment was conducted to determine if Cnr2-/- mice showed increased susceptibility to age related osteoarthritis. Histological analysis showed that OARSI score in the medial compartments of the knee joint was significantly higher in Cnr2-/- mice than wild type littermates (5.6 ± 0.5 vs. 3.5 ± 0.3, p=0.008) (Figure 3A and 3B). There was no significant difference in OARSI score in the lateral compartment however. When the OARSI scores were combined for both compartments the score was significantly higher in Cnr2-/- mice as compared with wild type (11.0 ± 0.8 vs. 8.5 ± 1.0,  p=0.043).  There was no significant difference in body weight between Cnr2-/- and wild type mice at age 12 months or any other time point, nor was there any obvious difference between genotypes in general health status, behaviour or locomotor activity. These results provide further evidence that Cnr2 deficiency is associated with an increased susceptibility to osteoarthritis. 

Effect of Cnr2 deficiency on subchondral bone in age related osteoarthritis 
Analysis of tibial subchondral trabecular bone of 12-month old WT and Cnr2-/- female mice showed no difference in any variable between genotypes (Table 3). Similarly, no significant differences were observed in the medial or lateral subchondral bone plate thickness between WT and Cnr2-/- mice (Table 3).

Effect of Cnr2 deficiency on proteoglycan production by articular chondrocytes
In order to gain an insight into the potential mechanism by which Cnr2 might predispose to osteoarthritis we performed an in vitro experiment in which we compared levels of proteoglycan production from cultured articular chondrocytes derived from Cnr2-/- mice and wild type littermates. This showed that Cnr2-/- derived chondrocytes produced significantly less proteoglycans than wild type chondrocytes (Figure 4).  





Table 3. MicroCT analysis of tibial subchondral bone in twelve month old wild type (WT) and Cnr2-/- mice.








	WT(n=5)	Cnr2-/-(n=5)
BV/TV (%)	14.82 ± 0.73 	14.04 ± 0.36
Tb.N (1/mm)	2.77 ± 0.12	2.64 ± 0.13
Tb.Th (m)	53.55 ± 1.74	53.48 ± 1.70
Tb.Sp (m)	259.36 ± 7.36	272.13 ± 10.29
Tb.Pf (1/mm)	9.77 ± 1.74	9.18 ± 2.37
Medial bone plate thickness (m)	141.89 ± 7.51	147.56 ± 6.01
Lateral bone plate thickness (m)	116.15 ± 2.55	121.38 ± 6.12




BV/TV: trabecular bone volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; Tb.Pf: trabecular pattern factor. Data is presented as means ± sem. There was no significant difference between genotype groups for any variable.





Synthesis of the results of the in vivo experiments by meta-analysis  
In order to gain an insight into the overall effect of the Cnr2 pathway in the pathogenesis of osteoarthritis, we performed a meta-analysis of the in vivo studies reported in this paper. Individually all three experiments yielded results favouring a role of the Cnr2 pathway in osteoarthritis with a pooled effect-estimate mean difference of 1.55 (95% confidence interval [CI]: 0.96, 2.14; p<0.00001) with no evidence of heterogeneity between studies (I2 = 0%, P = 0.46) (Figure 5). This provides strong evidence in favour of a pathogenic role for Cnr2 in the pathogenesis of osteoarthritis. 

Discussion
Over recent years there has been increasing interest in the potential role of cannabinoids and their receptors in the pathophysiology and treatment of joint diseases 25.  Cannabinoid receptors are expressed in bovine articular chondrocytes  ADDIN REFMGR.CITE 10 and in human synovial tissue  ADDIN REFMGR.CITE 11,26 along with the enzyme fatty acid amide hydrolase (FAAH) which is responsible for degradation of cannabinoids and other fatty acid amides  ADDIN REFMGR.CITE 11. Clinical studies have shown that the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are present in the synovial fluid of OA and RA patients but not in synovial fluid from normal volunteers  ADDIN REFMGR.CITE 11. Furthermore, various cannabinoid 

receptor ligands have been found to reduce cartilage damage and attenuate tissue injury in mouse models of inflammatory arthritis  ADDIN REFMGR.CITE 8,9 and to inhibit IL-1 induced degradation of cartilage matrix in vitro  ADDIN REFMGR.CITE 10. In addition, both receptors have been shown to play significant roles in the regulation of bone turnover and bone density in mice  ADDIN REFMGR.CITE 7,4,27,3,6,5,28. 
Despite this, the possible role of cannabinoids and their receptors in the pathogenesis of osteoarthritis has not previously been investigated, forming the rationale for the studies presented here. 
Our studies showed that mice with targeted deletion of Cnr2 developed significantly more severe osteoarthritis affecting the medial joint compartment following DMM as compared with wild type littermates. Although the scores that were observed in this study are lower than those previously reported in 129/SvEv mice 16 this is in keeping with previous observations which have suggested that C57BL/6 mice may be less susceptible to OA than some other mouse strains 29. Further evidence in favour of a pathogenic role for the type 2 cannabinoid receptor in DMM induced osteoarthritis came from the observation that treatment with HU308, an agonist of CB2 partially protected against the development of osteoarthritis in wild type mice. While the protective effects were predominantly observed in 


Figure 4. Proteoglycan production by WT and Cnr2-/- chondrocytes. Panel A shows proteoglycan deposition as assessed by Alcian blue staining from wild type (WT) and Cnr2-/- mice. Values are expressed as percent of the values observed in WT cultures. Panel B representative photomicrographs from cultures described in A. Columns represent means and vertical bars standard error of the mean from three separate experiments. The p-value refers to the difference between wilt type and Cnr2-/- assessed by Student’s t-test. 

the medial joint compartment, the effect remained significant when scores were combined for the whole joint. In contrast, HU308 had no protective effect in Cnr2-/- mice subjected to DMM which is consistent with the hypothesis that HU308 protected against OA by a Cnr2 specific mechanism. The importance of the pathway in the pathogenesis of osteoarthritis is further supported by the finding that 12 month old Cnr2-/- female mice that had not undergone any specific experimental procedures developed more severe osteoarthritis as compared with wild type littermates. Finally a meta-analysis which combined the results of all three in vivo experiments showed convincing evidence in favour of a pathogenic role for Cnr2 in osteoarthritis with no heterogeneity between studies. 
Although these experiments provide strong evidence to suggest that the Cnr2 pathway plays a role in osteoarthritis, further work will be required to investigate the mechanisms responsible. We had initially considered that the altered susceptibility to OA might be mediated by differences in the structure of subchondral bone, given that previous studies have shown that Cnr2 regulates bone mass and bone turnover  ADDIN REFMGR.CITE 7,6. Although we found subtle difference in subchondral bone between non-operated Cnr2-/- and wild type mice, there were no differences genotypes following DMM. Similarly, no differences in subchondral bone were observed between genotypes in 12 month old mice. The lack of an effect of DMM on subchondral bone reported in this study contrasts with the observations made by Kim and colleagues who reported that DMM is associated with an increase in trabecular bone volume of subchondral bone in the medial but not lateral joint compartment in C57BL/6 mice 30. It is possible that technical factors might have been responsible since the MicroCT was carried out in the transverse plane as opposed to the coronal plane used here. In addition Kim et al. analysed the medial and lateral compartments separately, whereas we analysed the whole of the tibial plateau.  
A possible explanation for the increased susceptibility of Cnr2-/- mice to osteoarthritis would be differences between genotypes in chondrocyte function or matrix production. In support of this hypothesis, we found that cultured chondrocytes from Cnr2-/- mice produced less proteoglycans in vitro than wild type chondrocytes. This raises the possibility that deficiency of Cnr2 might predispose to OA by altering the proteoglycan content of cartilage matrix, rendering it less able to deal with biomechanical stimuli. However, we cannot 


	
Figure 5. Meta-analysis on the role of Cnr2 pathway on osteoarthritis. Meta-analysis of the in vivo experiments performed in this study to evaluate the role of the Cnr2 pathway in osteoarthritis. The mean and standard deviation (SD) of the OARSI scores from individual experiments are shown. The squares represent the point estimate of the mean difference for each experiment and the bars represent the 95% confidence intervals. The weight indicates   how much influence each study has on the overall results. The diamond represents the summary effect from all three experiments combined. Heterogeneity was tested using the Cochran Q-statistic (chi-square) and quantified using the I2-statistic 35.





exclude the possibility that other mechanisms may also contribute and so further work will be required, possibly using tissue specific inactivation of Cnr2 to determine if the mechanism is chondrocyte specific or if other joint tissues are involved. 
In this regard, it is relevant to point out that an effect of Cnr2 on innervating neurons may also be operative, given that activation of CB2 has been shown to have anti-nociceptive effects in various experimental pain models  ADDIN REFMGR.CITE 31,32,33. 
The question also arises as to whether the increased susceptibility to OA was a direct consequence of Cnr2 inactivation or changes in expression of other genes and pathways that are regulated by Cnr2. In this regard we have previously shown that deletion of Cnr2 is associated with alterations in the patterns of expression of many genes some of which are located close to the site of the targeting event on chromosome 4 34. While it is possible that some of the effects we observed were indirect and mediated by changes in expression of genes regulated by Cnr2, the protective effect that we observed in response to HU308 treatment suggests that signalling through the Cnr2 receptor itself plays an important role. 



Whatever the underlying mechanism, the present studies demonstrate for the first time that the CB2 pathway plays a role in the pathogenesis of osteoarthritis in mice. While further research will be required to investigate the mechanisms responsible, our studies raise the possibility that manipulation of this pathway might be of therapeutic value in humans with the disease. 
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Supplementary Figure 1. Coronal section of the knee joint stained with Safranin-O and Haematoxylin. 



The region of interest of the trabecular subchondral bone analysed by micro-CT is outlined in black and subchondral bone plates are shown in white. LM: lateral meniscus; MM: medial meniscus.
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